Pharma Marketing's AI Reckoning: A New Commercialization Model Is Born

CHICAGO & NEW YORK – July 28, 2026 – In a move that signals a fundamental rewiring of the pharmaceutical commercialization engine, specialized agency CG Life has combined with The Considered+AI, a firm built from the ground up around generative artificial intelligence. The union is more than a standard acquisition; it represents a deliberate fusion of deep scientific expertise with an AI-native operating system, creating a new blueprint for how life-changing therapies are brought from the lab to the patient.

For decades, the model for launching a new drug has followed a well-worn path. But as science accelerates, producing highly specific therapies for rare and complex diseases, that legacy model is cracking under the strain. This combination aims to build the replacement, merging CG Life’s two decades of experience in the trenches of rare disease marketing with the disruptive speed and intelligence of an agency designed for the AI era.

The AI-Native Disruption

The term “AI-native” has become a popular buzzword, but The Considered+AI has given it tangible form. Founded in 2021 by David Hunt, a veteran of global healthcare communications, the agency was conceived not to use AI, but to be built around it. Unlike legacy firms retrofitting AI tools onto existing workflows, its entire operating model—from strategy and content creation to campaign optimization—is powered by an integrated AI framework. This approach, combined with a remote-first global talent model, has propelled the agency to double in size each year since its inception and earn the title of MM+M Small Agency of the Year for 2025.

“Breakthrough science deserves breakthrough commercialization,” said David Hunt, Founder of The Considered, in the official announcement. This statement cuts to the core of the agency’s philosophy. Its proprietary HealthControl™ framework uses AI to rapidly pressure-test strategic assumptions and move from market analysis to launch-ready ideas in weeks, not months. For clients like AstraZeneca, Novartis, and Sanofi, this has meant an unprecedented ability to experiment, learn, and adapt in real-time.

This is the engine CG Life is integrating into its chassis. “The future belongs not to the biggest agencies, but to those that amplify world-class talent through AI-native ways of working,” stated David Ormesher, CEO of CG Life. His vision is clear: this isn't about replacing human expertise but augmenting it. By automating repeatable tasks and providing deep, instantaneous data analysis, the AI-native model frees up senior strategists and creatives to focus on what humans do best: understanding nuance, building relationships, and making high-stakes judgment calls. The result is a smaller, more senior, and more impactful team for the client.

A New Blueprint for Rare Disease Commercialization

Nowhere are the stakes higher or the challenges more complex than in the world of rare and hard-to-treat diseases. This is CG Life’s home turf. For over 20 years, the agency has specialized in translating labyrinthine science for biopharma companies navigating the unique commercial landscape of precision medicine. With clients like Pfizer and Bio-Rad, it has proven its ability to build credibility and connect with niche communities.

“Success is no longer determined solely by clinical data,” Ormesher noted, highlighting a critical shift in the market. “It depends on helping patients, caregivers, physicians, and advocacy groups understand why a new therapy matters and how it can change lives.” This is a communications challenge of immense complexity. Patient populations are small and geographically scattered, the science is often esoteric, and trust is paramount.

This is where the fusion with The Considered+AI becomes a game-changer. The combined entity can now leverage AI to hyper-segment patient and physician communities, develop highly personalized educational content at scale, and monitor the digital ecosystem for the specific questions and concerns that define a rare disease journey. Instead of a one-size-fits-all launch strategy, they can orchestrate a dynamic, responsive campaign that feels personal and authentic to a community that is often overlooked.

As Ormesher put it, “Despite remarkable advances in science, too many therapies struggle to achieve their full potential due to commercialization strategies designed for a different era.” This new, AI-powered model is designed to break that cycle, ensuring that the most innovative science is matched with equally innovative marketing.

The Evolving Agency Landscape: Acquire or Be Disrupted?

This transaction is a microcosm of a larger tectonic shift occurring across the entire marketing services industry. For years, large holding companies have grown by acquiring smaller, specialized agencies. But the rise of AI introduces a new dynamic. An AI-native firm, even a small one, possesses an operational advantage that can be difficult for a larger, incumbent organization to replicate due to the immense challenge of cultural and structural change.

CG Life’s move is a strategic masterstroke in this new environment. Rather than attempting a slow and painful internal transformation, it has acquired the catalyst for that change. “Rather than gradually adapting to the AI era, this acquisition demonstrates CG Life's commitment to leading the transformation of scientific commercialization,” Ormesher explained. It is a decisive bet on an integrated future, positioning the combined firm against not only traditional pharma agencies but also tech-centric competitors like Real Chemistry and Klick Health, who are also making significant investments in AI.

The structure of the deal itself is telling. David Hunt will continue to lead The Considered as its CEO, will join the CG Life board, and remains a major shareholder. This is not a simple buyout but an integration of leadership and vision, designed to preserve the innovative culture that made The Considered successful while giving it the scale and scientific depth of CG Life.

This combination offers a potent answer to the question facing every agency leader today: how to stay relevant in an age of intelligent machines. The answer, it seems, is not to fear the technology but to fuse it with irreplaceable human insight. By blending CG Life's deep domain expertise with The Considered's AI-native agility, the new entity is creating a formidable commercialization partner purpose-built to help clients move faster from insight to action and connect more effectively with the people who matter most.